Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

NCT05022797 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped closed because of low recruitment

Conditions

Diffuse Large B-Cell Lymphoma
Drug Toxicity

Interventions

DRUG: Glucarpidase 1000 UNT [Voraxaze]

Sponsor

Fundacion CRIS de Investigación para Vencer el Cáncer

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]